PGY1 @UofUInternalMed Former Post-Doctoral Research Fellow @Huntsmancancer @UUtah 🇺🇸 MD 23' @usjliban 🇱🇧🇫🇷
Salt Lake City, Utah
Joined August 2023
- Tweets397
- Following344
- Followers331
- Likes950
Chadi Hage Chehade retweeted
Huge congratulations to my mentor and friend @neerajaiims on his election to the @ASCO Nominating Committee. A true leader whose humility, vision, and mentorship continue to inspire so many. @OncoAlert brnw.ch/21wYvzE
Chadi Hage Chehade retweeted
Delayed genomic testing limits access to life-prolonging cancer treatments. @chadihcmd @huntsmancancer joins @neerajaiims to discuss the utilization of next-generation sequencing in nearly 200,000 patients with common cancers having approved targeted therapies. #WatchNow on UroToday > bit.ly/4fOR7EX
Chadi Hage Chehade retweeted
Thrilled for Day 2 of invigorating discussions on prostate and renal cell cancer at #UromigosLive! by @tompowles1 @brian_rini @Uromigos @OncoAlert @urotoday
Chadi Hage Chehade retweeted
Excited to be part of @Uromigos LIVE & UnpluggD ‘25! Can’t wait for the lively, engaging, unfiltered, and insightful conversations that make this meeting so special @OncoAlert
Chadi Hage Chehade retweeted
Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit asco.org/election to learn more about the candidates and place your vote! Thank you!!
Chadi Hage Chehade retweeted
Proud to endorse my mentor and friend @neerajaiims for the @ASCO Nominating Committee! His humility, kindness, unwavering dedication to mentoring young investigators globally & advancing cancer research inspire me every day. A true leader who lifts everyone around him.
Chadi Hage Chehade retweeted
Delayed genomic testing limits access to life-prolonging cancer treatments. @chadihcmd @huntsmancancer joins @neerajaiims to discuss the utilization of next-generation sequencing in nearly 200,000 patients with common cancers having approved targeted therapies. #WatchNow on UroToday > bit.ly/4fOR7EX
Chadi Hage Chehade retweeted
Thank you Neeraj for reminding us of the importance of accessibility in NGS testing for metastatic prostate cancer. Equity must guide innovation. #IUCS25 @chadihcmd
@urologysummit @gbanna74 @ravikanesvaran @OncoAlert @ONCOassist @neerajaiims @PGrivasMDPhD @drenriquegrande @montypal @nataliagandur @alison_tree @ManiamAkash @Ecastromarcos @huntsmancancer
Chadi Hage Chehade retweeted
Delayed genomic testing limits access to life-prolonging cancer treatments. @chadihcmd @huntsmancancer joins @neerajaiims to discuss the utilization of next-generation sequencing in nearly 200,000 patients with common cancers having approved targeted therapies. #WatchNow on UroToday > bit.ly/4fOR7EX
Chadi Hage Chehade retweeted
Congrats to Dr. Chadi Hage Chehade on presenting at #ASCO25 on the timing and use of tumor next-generation sequencing testing for the 5 most common cancers in the U.S., and receiving the Conquer Cancer Merit Award! Check out his interview with @urotoday: lnkd.in/gJpDJyqk
Chadi Hage Chehade retweeted
🌟🌎 #GlobalGUFriday
🧬 PARP inhibitors: from ovarian cancer to a pan-tumor approach — Landmark phase III trials transforming care in HRR-mutated tumors.
@chadihcmd @ggebraelmd @nsayeghmd @ziremozay @SWOGadvocate
@JenniferLitton @umangtalking
@neerajaiims
📌 FDA/EMA approvals based on pivotal data:
🟣 Ovary – SOLO-1/2, PRIMA, PAOLA-1, ARIEL3 (maintenance & 1L combo)
🩷 Breast – OlympiA, EMBRACA (gBRCA early & metastatic)
🟡 Prostate – PROfound, PROpel, MAGNITUDE, TALAPRO-2 (mCRPC)
🟢 Pancreas – POLO (gBRCA mPDAC maintenance)
💡 Mechanism: Exploits DNA repair defects → synthetic lethality
📈 Benefit: OS & PFS gains across tumor types
🔍 Trends: Expanding into combinations (IO, ADCs), early stages, and basket trials
💡 Main messages:
1️⃣ Synthetic lethality is now a validated therapeutic principle across tumor types.
2️⃣ HRR testing (BRCA1/2, ATM, PALB2…) should be integrated into routine work-up.
3️⃣ Maintenance strategies prolong disease control and delay chemo.
4️⃣ Combinations with IO & ADCs may expand benefit beyond BRCA+ disease.
🩺 Clinical implications:
✔ Test early → identify candidates before progression.
✔ Cross-tumor genomic panels are now standard in advanced disease.
✔ Watch for hematologic toxicity, fatigue & GI AEs — require proactive management.
@OncoAlert @APCCC
#PARPinhibitors #DNArepair #PrecisionOncology #OncoTwitter #Medicalwatch
pubmed.ncbi.nlm.nih.gov/3979…
Chadi Hage Chehade retweeted
PARP inhibitors comprise a therapeutic class that targets PARP proteins involved in DNA repair. This #OpenAccess review of PARP inhibitor approvals emphasizes their efficacy across different cancers based on landmark phase 3 clinical trials.
🔗: acsjournals.onlinelibrary.wi…
Chadi Hage Chehade retweeted
Feeling Incredible honored to receive the #JQTF award!🌟
Huge thanks to my mentors @PGrivasMDPhD & JWright - Always inspired 💯
Grateful to @BladderCancerUS for advancing research & advocacy. 🙏
Congrats @AmandaMyersMD @Anto_cigliola @alexzhuDO @DrAndrewKatims #BCANTT25 👏
Chadi Hage Chehade retweeted
Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO.
Learn more about FASCO distinction: brnw.ch/21wUiVu
Chadi Hage Chehade retweeted
A very informative and detailed discussion on practice changing data and trial updates in bladder cancer by @PGrivasMDPhD #BestOfASCO 2025 in Boise! education.binaytara.org/cont…
Chadi Hage Chehade retweeted
Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh @PCFnews @urotoday @OncoAlert
Just in👉Two @TheLancetOncol papers on patient-reported QOL results in ph3 TALAPRO-2 trial👉in all-comer & HRR deficient mCRPC #ProstateCancer pts👉Improved OS without compromising QOL👇Links: bit.ly/3DWHlSR & bit.ly/3E3SSQi @urotoday @OncoAlert @PCFnews 👇
Chadi Hage Chehade retweeted
Real-world data show that only 30% to 40% of patients with the most common cancers receive NGS testing.
🗨️ “The ultimate goal would be for all patients to receive NGS testing earlier in their disease course," - @chadihcmd of @huntsmancancer told Healio.
bit.ly/4lzH2gU
Chadi Hage Chehade retweeted
Metformin did not boost survival in metastatic hormone-sensitive prostate cancer.
It did ease ADT’s metabolic side effects.
Not a game-changer, but still some hope for patient quality of life. #Oncology
With very nice editorial by @ggebraelmd @chadihcmd and @neerajaiims
@TheLancetOncol @APCCC_Lugano @Silke_Gillessen @Prof_Nick_James @AlisonBirtle @scserendipity1 @AttardLab @drdjmath @mattsydes
doi.org/10.1016/S1470-2045(2…
doi.org/10.1016/S1470-2045(2…
Chadi Hage Chehade retweeted
✏️@neerajaiims, @chadihcmd, and Georges Gebrael discuss the STAMPEDE trial in their linked comment
See here: thelancet.com/journals/lanon…
Chadi Hage Chehade retweeted
So honored to receive this prestigious award by @eaonc kudos to all investigators/staff who work hard to conduct trials globally! @PrECOGonc @NaomiHaas5 @MonikaJoshimd @JCensits @HutchPresident @nicoleflemingmd @Dr_AmerZeidan @BrainTumorDoc @shilpaonc @OncoAlert @TiansterZhang
Congratulations to @PGrivasMDPhD on receiving the 2025 Young Investigator Award from @eaonc! He's recognized for a distinguished record of innovative research, outstanding clinical practice, and unwavering dedication to advancing the field of genitourinary oncology.
